APMAdvances in Precision Medicine2424-85922424-9106WHIOCE PUBLISHING PTE. LTD.10.18063/APM.v11i4.1849ArticleResearch Progress on Antitumor Drugs Targeting BRD4https://artdesignp.com/journal/APM/11/4/10.18063/APM.v11i4.1849LuJingbo,WuTao20261142026-04-26Bromodomain and extra-terminal structures (BET) family proteins serve as critical epigenetic “readers,” among which BRD4 can recognize and bind acetylated histones, recruit transcription elongation-related complexes, and maintain high-level expression of various proto-oncogenes and superenhancer-associated genes, playing a pivotal role in the development of malignant tumors. In recent years, small-molecule inhibitors and protein degraders (PROTACs) targeting BRD4 have advanced rapidly, evolving from early dual-bromodomain (BD1/BD2) pan-BET inhibitors to BD1/BD2 selective inhibitors, BRD4 selective degraders, antibody-PROTAC conjugates, and BRD4-related dual-target drugs, demonstrating promising antitumor potential. However, limitations such as limited monotherapy efficacy, dose-limiting toxicity, and acquired resistance continue to constrain their clinical translation. This article systematically reviews the tumor biology functions of BRD4 and the theoretical foundations of its drug targeting, focusing on representative compounds of BRD4-targeting inhibitors and degraders, their antitumor mechanisms, and preclinical/clinical research progress. It also discusses novel strategies including BD2 selective inhibition, dual-target inhibition, antibody-PROTAC conjugation, and nanodelivery systems, as well as resistance mechanisms and combination therapy approaches, aiming to provide insights for further optimization of BRD4-targeted epigenetic therapies.BRD4,BET inhibitor,PROTAC,Protein degradation,Epigenetic therapy

[1] Qian H, Zhu M, Tan X, et al., 2023, Super-Enhancers and the Super-Enhancer Reader BRD4: Tumorigenic Factors and Therapeutic Targets. Cell Death Discovery, 9(1): 470. [2] Wang N, Wu R, Tang D, et al., 2021, The BET Family in Immunity and Disease. Signal Transduction and Targeted Therapy, 6(1): 23. [3] Zheng B, Gold S, Iwanaszko M, et al., 2023, Distinct Layers of BRD4-PTEFb Reveal Bromodomain-Independent Function in Transcriptional Regulation. Molecular Cell, 83(16): 2896–2910.e4. [4] Muhar M, Ebert A, Neumann T, et al., 2018, SLAM-seq Defines Direct Gene-Regulatory Functions of the BRD4-MYC Axis. Science, 360(6390): 800–805. [5] Wang J, Xu Y, Rao X, et al., 2022, BRD4-IRF1 Axis Regulates Chemoradiotherapy-Induced PD-L1 Expression and Immune Evasion in Non-Small Cell Lung Cancer. Clinical and Translational Medicine, 12(1): e718. [6] Delmore JE, Issa GC, Lemieux ME, et al., 2011, BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. Cell, 146(6): 904–917. [7] Filippakopoulos P, Qi J, Picaud S, et al., 2010, Selective Inhibition of BET Bromodomains. Nature, 468(7327): 1067–1073. [8] Mertz JA, Conery AR, Bryant BM, et al., 2011, Targeting MYC Dependence in Cancer by Inhibiting BET Bromodomains. Proceedings of the National Academy of Sciences, 108(40): 16669–16674. [9] Zuber J, Shi J, Wang E, et al., 2011, RNAi Screening Identifies Brd4 as a Therapeutic Target in Acute Myeloid Leukemia. Nature, 478(7370): 524–528. [10] Lee DU, Katavolos P, Palanisamy G, et al., 2016, Nonselective Inhibition of the Epigenetic Transcriptional Regulator BET Induces Marked Lymphoid and Hematopoietic Toxicity in Mice. Toxicology and Applied Pharmacology, 300: 47–54. [11] Riveiro ME, Astorgues-Xerri L, Vazquez R, et al., 2016, OTX015 (MK-8628), a Novel BET Inhibitor, Exhibits Antitumor Activity in Non-Small Cell and Small Cell Lung Cancer Models Harboring Different Oncogenic Mutations. Oncotarget, 7(51): 84675–84687. [12] Boi M, Gaudio E, Bonetti P, et al., 2015, The BET Bromodomain Inhibitor OTX015 Affects Pathogenic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. Clinical Cancer Research, 21(7): 1628–1638. [13] Ferraro E, Macri E, Zwergel C, et al., 2025, Inhibition of Bromodomain and Extra-Terminal Motif (BET) Proteins in Pediatric Sarcoma: A Systematic Review of In Vitro and In Vivo Studies. Drug Discovery Today, 30(12): 104516. [14] Tang P, Zhang J, Liu J, et al., 2021, Targeting Bromodomain and Extraterminal Proteins for Drug Discovery: From Current Progress to Technological Development. Journal of Medicinal Chemistry, 64(5): 2419–2435. [15] To KKW, Xing E, Larue RC, et al., 2023, BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications. Molecules, 28(7): 3043. [16] Yin M, Guo Y, Hu R, et al., 2020, A Potent BRD4 Inhibitor Suppresses Cancer Cell-Macrophage Interaction. Nature Communications, 11(1): 1833. [17] Liao M, Long K, Dong L, et al., 2025, Targeting CLEC4E in Immunosuppressive Tumor-Associated Macrophages via BET Inhibition. Clinical and Translational Medicine, 15(10): e70505. [18] Gilan O, Rioja I, Knezevic K, et al., 2020, Selective Targeting of BET Proteins’ BD1 and BD2 in Cancer and Immunoinflammation. Science, 368(6489): 387–394. [19] Zhang L, Cai T, Lin X, et al., 2021, Selective Inhibition of the Second Bromodomain of BET Family Proteins Results in Robust Antitumor Activity in Preclinical Models of Acute Myeloid Leukemia. Molecular Cancer Therapeutics, 20(10): 1809–1819. [20] Kati W, 2018, Abstract DDT01-05: ABBV-744: A First-in-Class Highly BDII-Selective BET Bromodomain Inhibitor. Cancer Research, 78(13_Supplement): DDT01–05. [21] Patel H, Hertzog J, Heller L, et al., 2023, Abstract 6264: NUV-868, a Novel BD2-Selective BET Inhibitor, in Combination with Enzalutamide or Olaparib, Inhibits the Growth of Solid Tumor Xenografts. Cancer Research, 83(7_Supplement): 6264. [22] Lu J, Qian Y, Altieri M, et al., 2015, Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4. Chemistry & Biology, 22(6): 755–763. [23] Nowak RP, DeAngelo SL, Buckley D, et al., 2018, Plasticity in Binding Confers Selectivity in Ligand-Induced Protein Degradation. Nature Chemical Biology, 14(7): 706–714. [24] Zengerle M, Chan KH, Ciulli A, 2015, Selective Small Molecule Induced Degradation of the BET Bromodomain Protein BRD4. ACS Chemical Biology, 10(8): 1770–1777. [25] Gadd MS, Testa A, Lucas X, et al., 2017, Structural Basis of PROTAC Cooperative Recognition for Selective Protein Degradation. Nature Chemical Biology, 13(5): 514–521. [26] Saenz DT, Fiskus W, Qian Y, et al., 2017, Novel BET Protein Proteolysis-Targeting Chimera Exhibits Superior Lethal Activity Compared to Bromodomain Inhibitor (BETi) against Post-Myeloproliferative Neoplasms Secondary (s) AML cells. Leukemia, 31(9): 1951–1961. [27] Qin C, Hu Y, Zhou B, et al., 2018, Discovery of QCA570 as an Exceptionally Potent and Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Bromodomain and Extra-Terminal (BET) Proteins Capable of Inducing Complete and Durable Tumor Regression. Journal of Medicinal Chemistry, 61(15): 6685–6704. [28] Maneiro M, Forte N, Shchepinova MM, et al., 2020, Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4. ACS Chemical Biology, 15(6): 1306–1312. [29] Wang L, Ke Y, He Q, et al., 2025, A Novel ROR1-Targeting Antibody-PROTAC Conjugate Promotes BRD4 Degradation for Solid Tumor Treatment. Theranostics, 15(4): 1238–1254. [30] Donati B, Lorenzini E, Ciarrocchi A, 2018, BRD4 and Cancer: Going Beyond Transcriptional Regulation. Molecular Cancer, 17(1): 164. [31] Zhang Y, Fong KW, Mao F, et al., 2024, Upregulation of PLK1 Overcomes BETi Resistance in Prostate Cancer by Triggering BRD4 Phosphorylation-Dependent Degradation During Mitosis. Cell Reports, 43(7): 114431. [32] Liu R, Wang X, Branigan TB, et al., 2025, BET Bromodomain Inhibition Reverses CDK4/6 Inhibitor Resistance in Estrogen Receptor–Positive Breast Cancer via Induction of miR-34a-5p. Clinical Cancer Research, 31(23): 5096–5110. [33] Pawar A, Gollavilli PN, Wang S, et al., 2018, Resistance to BET Inhibitors Leads to Alternative Therapeutic Vulnerabilities in Castration-Resistant Prostate Cancer. Cell Reports, 22(9): 2236–2245. [34] Marr AR, Halpin M, Corbin DL, et al., 2024, The Multi-CDK Inhibitor Dinaciclib Reverses Resistance to Bromo-and Extra-Terminal Domain (BET) Inhibitors in Acute Myeloid Leukemia by Inhibiting Wnt/β-catenin Signaling. Experimental Hematology & Oncology, 13(1): 27. [35] Jin X, Yan Y, Wang D, et al., 2018, DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4. Molecular Cell, 71(4): 592–605.e4. [36] Zhang P, Wang D, Zhao Y, et al., 2017, Intrinsic BET Inhibitor Resistance in SPOP-Mutated Prostate Cancer is Mediated by BET Protein Stabilization and AKT–mTORC1 Activation. Nature Medicine, 23(9): 1055–1062. [37] Wang W, Tang YA, Xiao Q, et al., 2021, Stromal Induction of BRD4 Phosphorylation Results in Chromatin Remodeling and BET Inhibitor Resistance in Colorectal Cancer. Nature Communications, 12(1): 4441. [38] Wang C, Zhang Y, Chen W, et al., 2024, Next-Generation Advanced PROTACs as Potential Therapeutic Agents in Cancer Therapy. Molecular Cancer, 23(1): 110. [39] Minko T, 2020, Nanoformulation of BRD4-Degrading PROTAC: Improving Druggability To Target the ‘Undruggable’ MYC in Pancreatic Cancer. Trends in Pharmacological Sciences, 41(10): 684–686.